BioArctic: CHMP reiterates positive opinion of Lecanemab in the EU - Redeye

Redeye is relieved to see that the CHMP reiterates its positive opinion of Lecanemab/Leqembi with no changes, and thus that the European Commission can resume its decision-making process. We don’t expect any more hurdles in the approval process and think that a positive share price reaction is warranted.

Länk till analysen i sin helhet: https://www.redeye.se/research/1085087/bioarctic-chmp-reiterates-positive-opinion-of-lecanemab-in-the-eu?utm_source=finwire&utm_medium=RSS